HCLTECH
11.1.2024 14:05:00 CET | Business Wire | Press release
HCLTech, a leading global technology company, will join forces with key stakeholders from across the globe at the 54th Annual Meeting of the World Economic Forum (WEF) in Davos from Jan. 15–19, 2024. The company will contribute to deliberations on this year’s theme of “Rebuilding Trust” and discovering solutions with transparency, consistency and accountability.
HCLTech will be represented by its Chairperson Roshni Nadar Malhotra, CEO and Managing Director C Vijayakumar, Chief Technology Officer Kalyan Kumar; Chief Growth Officer for Europe and Africa, Ashish Kumar Gupta; President, Digital Foundation Services, Jagadeshwar Gattu; Global Head, Financial Services, Srinivasan Seshadri; Chief Marketing Officer Jill Kouri and Global Head, Sustainability, Santhosh Jayaram.
HCLTech will once again host guests at its pavilion at the iconic Promenade 66 which will be fully powered by locally produced green energy, underscoring the company’s commitment to a sustainable planet. In addition to its differentiated portfolio of services across digital, engineering, cloud, AI and software, HCLTech will showcase its award-winning sustainability solution, Net Intelligent Zero (NIO), at the pavilion with a live data feed.
This year, HCLSoftware makes its WEF debut with a dedicated lounge within the HCLTech pavilion. Chief Revenue Officer Rajiv Shesh and Chief Product Officer Kalyan Kumar will lead the HCLSoftware contingent that will showcase its cutting-edge software solutions that help enterprises navigate digital transformation.
HCLTech will participate in and host a series of panels and sessions on the future of technology, sustainability, diversity and inclusion in line with its brand purpose of bringing together the best of technology and its people to supercharge progress.
- The highlight this year will be the ‘Heroes of Progress’ reception on Jan. 17 to honor WEF Global Shapers who are making significant contributions to the fields of environment, women’s empowerment, art and sustainability.
- Roshni Nadar Malhotra, Chairperson, HCLTech is discussing the global water cycle and the potential of water as an enabler for SDGs on a panel on 'Out of Balance with Water' on Jan. 17, 15:00-15:45, Congress Center.
- Srinivasan Seshadri, Chief Growth Officer and Global Head, Financial Services, HCLTech, will lead an affiliate session on ‘Banking on trust through transformative tech’ on Jan. 16, 10:15-11:15 at Dome C, Ice Village.
- HCLTech is conducting broadcast sessions at its pavilion on Jan. 16, 17 and 18, 13:00–13:45. Dr. Saikat Chaudhuri, Innovation, Strategy and Engineering Professor, UC Berkeley will be moderating all three sessions with key industry leaders on: technology-led disruption, opportunities and impact; diversity-led progress for the future workforce; purpose-led sustainability agenda.
Additionally, HCL Group and Uplink, the open innovation platform of WEF, will announce the winners of this year’s Aquapreneur Challenge as part of their ongoing partnership.
To learn more about HCLTech@WEF 2024 visit World Economic Forum (WEF) 2024 at Davos | HCLTech.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111423911/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom